title: Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes.
abstract: Prostaglandin F2α analogs, commonly prescribed for glaucoma treatment, have been shown to induce side effects such as cutaneous hypertrichosis and hyperpigmentation. Therefore, these medications have theoretic applications in the treatment of alopecia and disorders of hypopigmentation. We reviewed the literature to find original studies assessing the use of prostaglandin F2α analogs in these settings. Studies and reports were analyzed in regards to androgenic alopecia, alopecia areata, chemotherapy-induced alopecia, vitiligo, and hypopigmented scarring. Based on the results of these studies, and consideration of pathophysiologic mechanism, the most promising applications for prostaglandin F2α analogs include androgenic alopecia, chemotherapy-induced alopecia, and alopecia areata concurrently treated with corticosteroids.
authors.affiliation: David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
authors.forename: Young M
authors.initials: YM
authors.lastname: Choi
authors.affiliation: Division of Dermatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
authors.forename: Joseph
authors.initials: J
authors.lastname: Diehl
authors.affiliation: Division of Dermatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California. Electronic address: PLevins@mednet.ucla.edu.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Levins
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000505:Alopecia / Q000188:drug therapy*; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015237:Dinoprost / Q000502:physiology; D004195:Disease Models, Animal; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005140:Eyelashes / Q000187:drug effects; D005901:Glaucoma / Q000188:drug therapy; D018859:Hair Follicle / Q000187:drug effects; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D006983:Hypertrichosis / Q000139:chemically induced; D017496:Hypopigmentation / Q000188:drug therapy*; D008543:Melanins / Q000096:biosynthesis; D051379:Mice; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016037:Single-Blind Method
chemical_list: D000305:Adrenal Cortex Hormones; D000577:Amides; D008543:Melanins; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D015237:Dinoprost; D000069580:Bimatoprost
keywords: alopecia areata; androgenic alopecia; bimatoprost; glaucoma; latanoprost; prostaglandin; prostaglandin F2α analog; travoprost; vitiligo